MedTrace Logo

Strategic Transformation of the Market of HCV Treatments

NCT02961426 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 603

Last updated 2021-01-20

No results posted yet for this study

Summary

This is a Phase II/III, multicenter, multi-country, trial to assess the efficacy, safety, tolerance and pharmacokinetics of sofosbuvir plus ravidasvir for the treatment of HCV infection.

Conditions

  • Hepatitis C

Interventions

DRUG

sofosbuvir + ravidasvir

combination of sofosbuvir + ravidasvir

Sponsors & Collaborators

  • Ministry of Health, Malaysia

    collaborator OTHER_GOV

  • Ministry of Health, Thailand

    collaborator OTHER_GOV

  • National Science and Technology Development Agency, Thailand

    collaborator OTHER_GOV

  • Drugs for Neglected Diseases

    lead OTHER

Principal Investigators

  • Isabelle Andrieux-Meyer, MD · Drugs for Neglected Diseases

  • Soek-Siam Tan, MD · Selayang Hospital

  • Satawat Thongsawat, MD · Chiang Mai Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2021-08-31
Completion
2024-03-31

Countries

  • Malaysia
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02961426 on ClinicalTrials.gov